2010
DOI: 10.2217/nnm.10.112
|View full text |Cite
|
Sign up to set email alerts
|

Nanothermotherapy by High Performance Magnetic Nanoparticles

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
13
0

Year Published

2011
2011
2023
2023

Publication Types

Select...
6
1

Relationship

2
5

Authors

Journals

citations
Cited by 14 publications
(13 citation statements)
references
References 13 publications
0
13
0
Order By: Relevance
“…administration of Taxotere Ò and the TPGS-emulsified PLA-TPGS NPs formulation by using SD rats at the same Docetaxel dose of 10 mg/kg, which demonstrated the great advantages of the nanoparticle formulation vs. Taxotere Ò : lower pick concentration in the plasma of 7250 vs. 14,990 ng/mL, much larger AUC of 3.92 9 10 5 vs. 1.14 9 10 5 ng h/mL, and much longer half-life of 83.87 vs. 4.17 h with much smaller AUC associated with the drug concentration above the maximum tolerance of 19% vs. 84%. 10 Other key proof-of-concept experimental results obtained so far include (1) effects of particle size and surface coating on cellular uptake of nanoparticles, (2) nanoparticle formulation for oral chemotherapy, 7,8,29 (3) nanoparticles for drug delivery across the BBB, 9,11 and (4) nanoparticles formulation of iron oxides (IOs) or/and quantum dots (QDs) for enhanced MRI, fluorescence imaging, and multimodal imaging. 18,21,23 .…”
Section: Proof-of-concept Experimental Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…administration of Taxotere Ò and the TPGS-emulsified PLA-TPGS NPs formulation by using SD rats at the same Docetaxel dose of 10 mg/kg, which demonstrated the great advantages of the nanoparticle formulation vs. Taxotere Ò : lower pick concentration in the plasma of 7250 vs. 14,990 ng/mL, much larger AUC of 3.92 9 10 5 vs. 1.14 9 10 5 ng h/mL, and much longer half-life of 83.87 vs. 4.17 h with much smaller AUC associated with the drug concentration above the maximum tolerance of 19% vs. 84%. 10 Other key proof-of-concept experimental results obtained so far include (1) effects of particle size and surface coating on cellular uptake of nanoparticles, (2) nanoparticle formulation for oral chemotherapy, 7,8,29 (3) nanoparticles for drug delivery across the BBB, 9,11 and (4) nanoparticles formulation of iron oxides (IOs) or/and quantum dots (QDs) for enhanced MRI, fluorescence imaging, and multimodal imaging. 18,21,23 .…”
Section: Proof-of-concept Experimental Resultsmentioning
confidence: 99%
“…The best result has realized 91.3% oral bioavailability of Docetaxel by PLA-TPGS nanoparticle formulation. 7,8,29 Similarly, delivery of imaging and therapeutic agents across the BBB can be realized by nanoparticles formulation and surface modification for targeting. The effects of particle size and surface functionalization have been systematically investigated and transferrin surface conjugation can have significant effects (Fig.…”
Section: Proof-of-concept Experimental Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Recent investigations have shown that the efficacy of PTT is strongly related to the intracellular concentration of gold nanostructures rather than to the extracellular concentration. 35,36 Therefore, increasing the cellular uptake of gold nanostructures is crucial for improving the therapeutic effect of PTT against tumor cells. However, most gold nanostructures modified by polyethylene glycol (PEG) are resistant to being internalized due to their high hydrophobicity and neutral surface potential.…”
Section: Introductionmentioning
confidence: 99%
“…With the explosive growth of nanotechnology, magnetic nanothermotherapy, also termed magnetic fluid hyperthermia (MFH) or magnetic nanoparticles (MNPs) hyperthermia (MNH), has been making rapid progress ( 15 ). The research output of MFH has been successfully applied in clinical oncology ( 16 ).…”
Section: Introductionmentioning
confidence: 99%